Literature DB >> 21703187

Liver disease in adult patients with cystic fibrosis: a frequent and independent prognostic factor associated with death or lung transplantation.

Ariane Chryssostalis1, Dominique Hubert, Joël Coste, Reem Kanaan, Pierre-Régis Burgel, Nadine Desmazes-Dufeu, Olivier Soubrane, Daniel Dusser, Philippe Sogni.   

Abstract

BACKGROUND & AIMS: Increased life expectancy in patients with cystic fibrosis (CF) allows better knowledge of non-pulmonary complications like liver disease (CFLD). However, few data have been published in large adult cohorts. The aim of this study was to estimate the prevalence and the prognosis of CFLD in adult CF patients.
METHODS: A retrospective analysis of a monocentric cohort of adult CF patients prospectively followed, at least every year, was performed. CFLD was diagnosed using published composite criteria. If cirrhosis was suspected, upper digestive endoscopy was realized to assess the presence of portal hypertension.
RESULTS: A cohort of 285 adult CF patients was followed during 4.8 ± 3.6 years. Among them, 90 had CFLD at the beginning of follow-up and 23 a suspicion of cirrhosis. Factors independently associated with liver disease at baseline were history of meconium ileus, pancreatic insufficiency, chronic colonization with Burkholderia cepacia and the number of IV antibiotic courses per year. Nine patients developed liver decompensation during follow-up, all with a suspicion of cirrhosis at baseline. Six patients underwent liver transplantation alone and three patients combined liver and lung transplantation. Factors independently associated with death or lung transplantation at baseline were liver disease, BMI, forced expiratory volume in 1 second and number of IV antibiotic courses per year.
CONCLUSIONS: CFLD was present at baseline in one third of adult patients with CF with a marked risk of liver decompensation during follow-up. Moreover, CFLD at baseline appears as an independent factor associated with death or lung transplantation.
Copyright © 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21703187     DOI: 10.1016/j.jhep.2011.03.028

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  18 in total

Review 1.  Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases.

Authors:  Luca Fabris; Romina Fiorotto; Carlo Spirli; Massimiliano Cadamuro; Valeria Mariotti; Maria J Perugorria; Jesus M Banales; Mario Strazzabosco
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-08       Impact factor: 46.802

Review 2.  Undiagnosed liver diseases.

Authors:  Emily Gao; Julian Hercun; Theo Heller; Sílvia Vilarinho
Journal:  Transl Gastroenterol Hepatol       Date:  2021-04-05

3.  A 10-Year united network for organ sharing review of mortality and risk factors in young children awaiting liver transplantation.

Authors:  Daniel H Leung; Amrita Narang; Charles G Minard; Girish Hiremath; John A Goss; Ross Shepherd
Journal:  Liver Transpl       Date:  2016-11       Impact factor: 5.799

4.  Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis.

Authors:  Matthew D Sadler; Pam Crotty; Linda Fatovich; Stephanie Wilson; Harvey R Rabin; Robert P Myers
Journal:  Can J Gastroenterol Hepatol       Date:  2015-04

5.  CFTR dysfunction predisposes to fibrotic liver disease in a murine model.

Authors:  Camilia R Martin; Munir M Zaman; Gyanprakash A Ketwaroo; Abdul Q Bhutta; Emmanuel Coronel; Yury Popov; Detlef Schuppan; Steven D Freedman
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-06-07       Impact factor: 4.052

Review 6.  Cystic fibrosis liver disease: A condition in need of structured transition and continuity of care.

Authors:  Julian Hercun; Fernando Alvarez; Catherine Vincent; Marc Bilodeau
Journal:  Can Liver J       Date:  2019-08-27

7.  Variceal Hemorrhage and Adverse Liver Outcomes in Patients With Cystic Fibrosis Cirrhosis.

Authors:  Wen Ye; Michael R Narkewicz; Daniel H Leung; Wikrom Karnsakul; Karen F Murray; Estella M Alonso; John C Magee; Sarah Jane Schwarzenberg; Alexander Weymann; Jean P Molleston
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-01       Impact factor: 2.839

Review 8.  Cirrhosis and other liver disease in cystic fibrosis.

Authors:  Thomas Flass; Michael R Narkewicz
Journal:  J Cyst Fibros       Date:  2012-12-20       Impact factor: 5.482

9.  Paeoniflorin regulates macrophage activation in dimethylnitrosamine-induced liver fibrosis in rats.

Authors:  Xiaorong Chen; Cheng Liu; Yunfei Lu; Zongguo Yang; Zhen Lv; Qingnian Xu; Qi Pan; Lingqing Lu
Journal:  BMC Complement Altern Med       Date:  2012-12-13       Impact factor: 3.659

Review 10.  Cystic fibrosis related liver disease--another black box in hepatology.

Authors:  Katharina Staufer; Emina Halilbasic; Michael Trauner; Lili Kazemi-Shirazi
Journal:  Int J Mol Sci       Date:  2014-08-04       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.